<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466270</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU 97211</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT01466270</nct_id>
  </id_info>
  <brief_title>Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction</brief_title>
  <official_title>A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Donepezil hydrochloride may help lessen cognitive dysfunction caused by
      chemotherapy.

      PURPOSE: This phase II trial is studying donepezil hydrochloride in treating cognitive
      dysfunction after chemotherapy in female breast cancer survivors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of conducting a randomized placebo-controlled clinical trial
           for cognitive symptoms in female breast cancer survivors.

      Secondary

        -  Estimate the variability of the clinical outcomes (FACT-Cognition Perceived Cognitive
           Impairment subscale, neurocognitive battery, FACIT-Fatigue, FACT Cog Total Score, PROMIS
           Fatigue, Epworth Sleepiness Scale, Beck Depression Inventory, Beck Anxiety Inventory,
           and RAND Short Form-36).

        -  Estimate the within patient correlation over time of the clinical outcomes.

        -  Obtain preliminary estimates of the effect of donepezil on the primary and secondary
           outcome variables.

        -  Correlate the reports of fatigue, sleep disturbance, and mood with measures of cognitive
           symptoms and neurocognitive test performance.

        -  Document the severity of cognitive symptoms and functional impairment in female breast
           cancer survivors who enroll on this pilot study.

        -  Correlate cognitive symptoms with cognitive test performance.

        -  Document the toxicities associated with donepezil hydrochloride use.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to menopausal status (pre- vs peri-/post-menopausal) and time since
      end of chemotherapy (12-36 months vs 36.01-60 months).

      Arm I: Patients receive donepezil hydrochloride orally (PO) once daily (QD).

      Arm II: Patients receive placebo PO QD.

      In both arms treatment continues for 24 weeks.

      Patients complete the entire battery of neurocognitive tests and questionnaires
      (FACT-Cognition Perceived Cognitive Impairment subscale, neurocognitive battery,
      FACIT-Fatigue, FACT Cog Total Score, PROMIS Fatigue, Epworth Sleepiness Scale, Beck
      Depression Inventory, Beck Anxiety Inventory, and RAND Short Form-36) at baseline
      (pre-treatment), 24 weeks (end of medication), and 36 weeks (end of wash-out).

      After completion of therapy, patients are followed at 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Retention is the percentage of participants who stay in the study for 24 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compliance is the percentage of pills taken while on study (based on returned diaries)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HVLT-IR</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hopkins verbal learning test - immediate recall is the number of words (of 12) than can be remembers during three tries. The total score ranges from 0 to 36. Higher is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fatigue is quantified by the FACIT-Fatigue scale. It consists of 13 questions answered on a 0 to 4 point scale. The fatigue score is the sum of the responses (some reverse scored) so that higher values represent less fatigue.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Anxiety Disorder</condition>
  <condition>Breast Cancer</condition>
  <condition>Cognition Disorders</condition>
  <condition>Depression</condition>
  <condition>Fatigue</condition>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive donepezil hydrochloride PO QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Donepezil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Adults &gt;18 years old.

          -  Female with history of invasive breast cancer

          -  Must have completed adjuvant chemotherapy between 1 and 5 years prior to registration

          -  Received at least 4 cycles of cytotoxic chemotherapy

          -  Documentation of prior chemotherapy

          -  Patients receiving ongoing hormonal therapy for breast cancer must be on the same
             hormonal agent for at least 3 months prior to study registration and continue for the
             duration of the study (9 months)

          -  Karnofsky Performance Status must be &gt; 60 or ECOG 0-2.

          -  Use of psychotropic medications (anti-depressants, anxiolytics, sleeping aids,
             narcotics) is permitted. Patient will be asked to list any that have been taken within
             the last 3 days on the recent medication sheet.

          -  Patients must be able to give informed consent to participate in the study, including
             signing the consent form.

          -  Self-reported cognitive disruption (FACT-Cog Version 3 Perceived Cognitive Impairments
             sub-score of &lt; 63)

          -  Negative serum pregnancy test within 10 days prior to registration for women of
             child-bearing potential.

        EXCLUSION CRITERIA:

          -  Evidence or suspected recurrent or metastatic disease

          -  History of dementia, Alzheimer's disease, multi-infarct dementia or CVA (history of
             transient ischemic attack (TIA is allowed)

          -  Current use of donepezil, galantamine, rivastigmine, tacrine, memantine,
             methylphenidate, dextroamphetamine, or any other specific cognition enhancing
             drugs.are not allowed. For patients who have used these medications they must not have
             used them within 4 weeks prior to registration.

        Patients may not currently be taking Ketoconazole or Quinidine

          -  Hypersensitivity to donepezil.

          -  Use of investigational medications within the last 30 days.

          -  Prior brain metastasis

          -  Traumatic brain injury, multiple sclerosis or recent myocardial infarction

          -  History of schizophrenia, psychosis or substance abuse

          -  Untreated current severe depression. (Currently treated depression is permitted if
             treatment is stable.)

          -  Acute severe fatigue, chronic fatigue syndrome or fibromyalgia.

          -  History of hepatic or renal dysfunction or disease

          -  Pregnant women are excluded from this study. The effects of donepezil on the
             developing human fetus at the recommended therapeutic dose are unknown. For this
             reason and because donepezil is known to be teratogenic, women of child-bearing
             potential must agree to use adequate contraception (hormonal or barrier method of
             birth control; abstinence) prior to study entry and for the duration of study
             participation. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her study physician immediately.

          -  It is unknown whether donepezil is excreted in breast milk, for this reason women who
             are currently breast-feeding are not eligible for this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia A. Lawrence</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2011</study_first_posted>
  <results_first_submitted>December 31, 2014</results_first_submitted>
  <results_first_submitted_qc>December 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2015</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fatigue</keyword>
  <keyword>sleep disorders</keyword>
  <keyword>depression</keyword>
  <keyword>anxiety disorder</keyword>
  <keyword>cognitive/functional effects</keyword>
  <keyword>breast cancer</keyword>
  <keyword>cancer survivor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued between 7/12 and 1/13 from CCOP sites across the nation.</recruitment_details>
      <pre_assignment_details>No wash-out or run-in period. All enrolled patients were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Donepezil</title>
          <description>Patients receive donepezil hydrochloride PO QD.</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Placebo</title>
          <description>Patients receive placebo PO QD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Donepezil</title>
          <description>Patients receive donepezil hydrochloride PO QD.</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Placebo</title>
          <description>Patients receive placebo PO QD.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="39" upper_limit="79"/>
                    <measurement group_id="B2" value="56" lower_limit="41" upper_limit="78"/>
                    <measurement group_id="B3" value="56" lower_limit="39" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention</title>
        <description>Retention is the percentage of participants who stay in the study for 24 weeks.</description>
        <time_frame>24 Weeks</time_frame>
        <population>All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive donepezil hydrochloride PO QD.
donepezil hydrochloride: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive placebo PO QD.
Placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Retention</title>
          <description>Retention is the percentage of participants who stay in the study for 24 weeks.</description>
          <population>All randomized patients</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="8.3"/>
                    <measurement group_id="O2" value="80.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance</title>
        <description>Compliance is the percentage of pills taken while on study (based on returned diaries)</description>
        <time_frame>24 weeks</time_frame>
        <population>Participants who returned pill diaries. Note that some participants did not return diaries so the numbers of participants for this analysis may not agree with the numbers for other analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Donepezil</title>
            <description>Patients receive donepezil hydrochloride PO QD.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance</title>
          <description>Compliance is the percentage of pills taken while on study (based on returned diaries)</description>
          <population>Participants who returned pill diaries. Note that some participants did not return diaries so the numbers of participants for this analysis may not agree with the numbers for other analyses.</population>
          <units>percentage of pills</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="89.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.0" lower_limit="89.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HVLT-IR</title>
        <description>Hopkins verbal learning test - immediate recall is the number of words (of 12) than can be remembers during three tries. The total score ranges from 0 to 36. Higher is better.</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized participants except two who did not provide any data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Donepezil</title>
            <description>Patients receive donepezil hydrochloride PO QD.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>HVLT-IR</title>
          <description>Hopkins verbal learning test - immediate recall is the number of words (of 12) than can be remembers during three tries. The total score ranges from 0 to 36. Higher is better.</description>
          <population>All randomized participants except two who did not provide any data.</population>
          <units>number of words recalled</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.58" spread="1.36"/>
                    <measurement group_id="O2" value="22.94" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue</title>
        <description>Fatigue is quantified by the FACIT-Fatigue scale. It consists of 13 questions answered on a 0 to 4 point scale. The fatigue score is the sum of the responses (some reverse scored) so that higher values represent less fatigue.</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized participants except two who did not provide any data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Donepezil</title>
            <description>Patients receive donepezil hydrochloride PO QD.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive placebo PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue</title>
          <description>Fatigue is quantified by the FACIT-Fatigue scale. It consists of 13 questions answered on a 0 to 4 point scale. The fatigue score is the sum of the responses (some reverse scored) so that higher values represent less fatigue.</description>
          <population>All randomized participants except two who did not provide any data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.89" spread="2.20"/>
                    <measurement group_id="O2" value="35.51" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 weeks (one month following the end of the study)</time_frame>
      <desc>The numbers of participants for this analysis may not agree with the numbers for the other analyses as not all participants completed their AE/toxicity evaluations.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Donepezil</title>
          <description>Patients receive donepezil hydrochloride PO QD.</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Placebo</title>
          <description>Patients receive placebo PO QD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain: Chest Wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="49" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E2" events="49" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="28"/>
                <counts group_id="E2" events="49" subjects_affected="21" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="28"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain: joint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-1048</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

